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Summary
Objective: The present cross sectional study was performed to test the hypothesis that in osteoarthritis (OA) of the knee severity of this
disease is related to local levels of inflammatory metabolites and their corresponding enzymes.
Methods: From 41 patients with OA of the knee (age range 45–79 years) undergoing arthroscopy blood, synovial fluid (SF) and synovial
membrane (SM) were collected. Clinical conditions were primarily assessed by the WOMAC-index and radiographic grading (K&L-grade).
Concentrations of PGE2, TxB2 and NO2/3 and that of IL-6, IL-1, IL-1, TNF, COX-2 and iNOS were determined in SF and SM, respectively.
Results: With advancing age K&L-grade and COX-2 in SM increased significantly (P=0.005 and P=0.01, respectively). TNF and IL-1 were
not detectable in SM samples. Apart from a correlation between PGE2 and WOMAC-index (r=0.36, P=0.035) no significant relationships
could be found between the various inflammatory parameters and any of the assessed clinical signs.
Conclusions: Apparently no direct relationships exist between the measured markers of inflammation (e.g. PGE2, NO2/3) or the involved
enzymes (e.g. COX-2, iNOS) and the severity of OA of the knee. The degenerative condition of this disease might be due to the more local,
mainly mechanical injury with little systemic upset. However, further longitudinal studies are needed to clarify whether the assessed
biochemical markers could serve as predictors for the progression of OA.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is characterized by progressive degen-
erative changes of joints. OA of the knee is one of the most
common forms of arthritis in synovial joints and it is more
frequently present in the elderly1–3. Synovitis in arthritic
joints is thought to play a dominant role in the development
of pain, joint inflammation and cartilage destruction4,5.
Furthermore, prostaglandin E2 (PGE2) and nitric oxide(NO) have been described as mediators of inflammation
and cartilage destruction6–8. Proinflammatory cytokines,
e.g. interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor
necrosis factor  (TNF), induce the expression of
cyclooxygenase-2 (COX-2) and nitric oxide synthase
(NOS), especially the inducible isoform of NOS (iNOS)9.
COX-2 and iNOS are responsible for increased levels
of PGE2 and NO which both play important roles in
inflammation and pain10–13. Therefore it could be antici-
pated that severity of OA will be related to local prostanoid
levels and/or other proinflammatory messengers.
While production of proinflammatory cytokines and other
inflammatory mediators in synovial fluid of joints is well
documented in OA14,15, the local concentrations of inflam-
matory parameters in OA of the knee and especially their
relation to clinical and radiographic signs have been rarely
investigated. Thus, the present cross sectional study was
performed in order to test the hypothesis that in patients
with OA severity of this disease assessed by the most
useful tools, such as the WOMAC-index16,17 and radio-
graphic grading18, is associated with the levels of local
markers of inflammation, such as PGE2, NO, COX-2 or
iNOS. Furthermore, we wanted to find out whether such
putative associations were influenced by the age of the
patient.
Materials and methods
PATIENTS
Forty-one Caucasian patients (16 males and 25 females)
with OA of the knee were included in the present cross
sectional study. Arthroscopy of the knee was performed for
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diagnostic and/or therapeutic reasons. The age of patients
ranged from 45 to 79 years; 16 patients were above 65
(median 70) and 25 patients were below 65 (median 54)
years. Mean body mass index (BMI) was in the upper
normal range (mean±SD: 27.8±4.5; median 27.6). Diagno-
sis of OA was based on the criteria of the American College
of Rheumatology19,20. In addition to knee pain at least
three of the following five characteristics had to be present:
morning stiffness for less than 30 min, crepitus, bony ten-
derness, bony enlargement, no palpable warmth. Joint
effusion was observed in 10 patients. In 14 patients taking
NSAIDs (N=11) and/or corticosteroids (N=4) these medica-
tions were withdrawn at least 48 h (NSAIDs) or at least 1
week (corticosteroids) prior to arthroscopy. The character-
istics of the patients are summarized in Table I. Written
informed consent was obtained from each patient. The
study was designed as an open, explorative, cross sec-
tional trial and it was conducted according to the Declara-
tion of Helsinki (as revised in 1996). The protocol was
approved by the local ethics board (Landesa¨rztekammer
Baden-Wu¨rttemberg, Stuttgart/Germany).
ASSESSMENT OF CLINICAL SYMPTOMS AND PAIN
For the assessment of the patients’ pain, stiffness and
physical function the German version of the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) was used17,21–23. The WOMAC-index is a ques-
tionnaire consisting of three different subscales for the
assessment of pain, stiffness and function of the affected
knee. The individual scores range from 0 (most troubles) to
100 (no troubles). A Visual Analog Scale (VAS) with end-
point markings of 0 = ‘no pain’ and 100=‘worst pain that
can be imagined’ was used to assess pain in the affected
knee at rest during the week before undergoing arthros-
copy. In addition, a subscale of the WOMAC-index was
taken to assess “WOMAC pain” which describes pain in
every day’s life activity of the patient (100=no pain, 0=worst
pain). According to Kellgren and Lawrence18,24 radio-
graphic grading was performed in preoperative radiographs
of the knee joints to assess the severity of OA in the
affected knee (score 0=normal; 4=most severe). In order to
avoid differences in the evaluation in each patient com-
plete radiographic grading was performed by the same
physician.
BIOLOGICAL SAMPLING
Before arthroscopy venous blood samples of all patients
were collected. Analysis of CRP in serum was performed
using heterogeneous sandwich enzyme immunoassay
testing (Vitros Products Chemistry, Johnson & Johnson
Clinical Diagnostics, Inc., Neckargemu¨nd, Germany).
Immediately prior to arthroscopy samples of undiluted
synovial fluid were taken by puncture of the knee joint.
During the therapeutic arthroscopy samples of synovial
membrane typical for this disease were obtained as ‘surgi-
cal waste’. For therapeutical and ethical reasons only small
parts of damaged synovial membrane could be collected.
The limited amounts of this material were not sufficient for
the complete biochemical measurements in all patients.
Synovial fluid and synovial membranes were immediately
frozen in liquid nitrogen and stored at −80°C.
BIOCHEMICAL PARAMETERS
In an isotope dilution assay concentrations of PGE2 and
TxB2 were determined in synovial fluid by using specific
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gas chromatography/triple stage quadrupole mass spec-
trometry (GC/MS/MS) as described by Schweer et al.25.
Initially synovial fluid (500 µl) was diluted with water
(500 µl) and deuterated internal standards (about 1 ng
each) were added. Further sample cleanup and
derivatization was performed as published recently25.
Relative expression levels of IL-6, IL-1, IL-1, TNF,
COX-2 and iNOS were determined using Taqman-PCR
techniques with RNA isolation from synovial membrane
and reverse transcriptase polymerase chain reaction
(RT-PCR). Total RNA from synovial tissue was isolated
combining phenol chloroform extraction (peqGold RNA
pure, Peqlab, Erlangen, Germany) and High Pure RNA
Isolation Kit (Roche Diagnostics, Mannheim, Germany).
The isolation was performed according to the manufactur-
ers’ instructions. Briefly, small pieces of synovial membrane
were disrupted in 600 µl phenol reagent using a mixer mill
MM300 (Retsch, Hilden, Germany) and 3 mm tungsten
carbide beads. After homogenization 250 µl of chloroform
was added and aqueous phase containing RNA was separ-
ated by centrifugation. The RNA containing solution was
diluted with ethanol and loaded on affinity columns (Roche
Diagnostics, Mannheim, Germany). The RNA isolation was
performed following the supplier standard protocol including
the specific DNase (Quiagen) digestion step to avoid
genomic DNA contamination. Finally, RNA was eluted with
50 µl DEPC treated water (Ambion Inc., Austin, Texas, USA)
and used as a template for cDNA synthesis. To generate
cDNA, RNA was reversed-transcribed using RAV2-reverse
polymerase (Amersham, Freiburg, Germany) and random
hexanucleotide primers (Roche Diagnostics, Mannheim,
Germany). Equal portions of the first strand synthesis reac-
tion were used for the following quantitative PCR-analysis.
PCR reactions, using the ABI SDS 7900 HT instrument
(Applied Biosystems, Foster City, CA, USA), were per-
formed in a total volume of 25 µl in a 96 well plate. For all
genes the final reaction mix contained: TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA,
USA), forward and reverse primers at final concentrations
of 0.9 µM for each primer, the corresponding probe at the
final concentration of 0.2 µM. TaqMan primers and probes
(Applied Biosystems, Foster City, CA, USA) for iNOS,
COX-2, TNF-, 18S were designed using Primer Express
software (Applied Biosystems, Foster City, CA, USA). This
program selects primer and probes sets with optimized
melting temperatures, secondary structure, base com-
position, and amplicon lengths. Sequences of primer and
probes and the flurogenic labels are listed in the Table I.
Primers and probes for IL-1, IL-1 and IL-6 were acquired
as Pre-Developed TaqMan Assay Reagents (Applied
Biosystems, Foster City, CA, USA) and used according to
the manufacturers’ instructions. For all PCRs 10 ng cDNA
was added to the reaction mix. A no template control (NTC)
that contained all the above reagents except cDNA was
included to detect the presence of contaminating DNA. All
experiments were performed in triplicate. Amplification and
fluorescence detection were conducted with a standard
program of 40 cycles. A result was defined negative when
no amplification occurred, i.e. the threshold cycle (Ct) value
was greater than 40 cycles. For standardization of the gene
expression level as determined by TaqMan analysis all
PCRs were performed as multiplex reactions. 18S rRNA
was quantified as an internal standard. Results are pre-
sented in relation to the expression of 18S rRNA (gene
expression/18S expression×106).
For the detection of NO2 and NO3 aliquots of synovial
fluid were centrifuged through a 10.000D ultrafree filter
(BIOMAX 10, Millipore, Eschborn, Germany) to remove any
hemoglobin due to erythrocyte lysis (4°C, 30 min,
10.000 g). NO2/3 concentrations were determined using the
Griess assay26,27: 80 µl of ultrafiltrate were used in the
assay. NO3 was reduced to NO2 by mix 1 consisting
of 0.08 U/ml nitrate reductase (Boehringer, Mannheim,
Germany), 530 µM FAD (Sigma, Munich, Germany) and
83 µM NADPH (Sigma, Munich, Germany) in a total volume
of 10 µl. Incubation was carried out 15 min at 37°C in a 96
well microtiter plate. Interfering NADPH was depleted 5 min
at 37°C by mix 2 consisting of 1104 U/ml lactate dehydro-
genase (Sigma, Munich, Germany) and 320 mM sodium
pyruvate (Sigma, Munich, Germany) in a volume of 10 µl.
The reaction was abrogated by the addition of 10 µl 1%
sulfanilamide (Sigma, Munich, Germany) in 0.1N HCl and
10 µl 0.1% N-(1 naphthyl)ethylenediamine (Sigma, Munich,
Germany). Following a 10 min incubation at room tempera-
ture in a microplate reader (Wallac, Turku, Finland) absorb-
ance was read at 544 nm in reference to 690 nm. NO2/3
concentrations were calculated by using a sodium nitrate
standard curve (1–32 µM) in H2O.
HISTOLOGIC GRADING
Samples of synovial membrane were intraoperatively
collected, immediately fixed in formalin and embedded in
paraffin according to standard procedures. Tissue sections
(3–4 µ) were prepared from each specimen and stained
with hematoxyline & eosin. The inflammatory reaction
(acute or chronic) was classified as absent (=0), low (=1),
moderate (=2) or strong (=3) as described previously28,29.
A Histo score was formed by adding of the two values
(acute+chronic inflammatory reaction).
STATISTICAL ANALYSIS
Results are presented as medians and arithmetic
means±standard deviations (SD). Groups of patients were
compared by using the Mann–Whitney U test. Correlations
between the various biochemical markers were tested
for significance by Spearman rank correlation test.
Associations between clinical features (WOMAC-index,
K&L grade) and markers of inflammation (PGE2, NO2/3 in
SF; COX-2, iNOS in SM) were evaluated by multiple linear
regression analysis taking into account the potential con-
founding factors/variables age and BMI. A result was con-
sidered to be significant if P was less than 0.05. All
statistical analysis was performed using either GraphPad
InStat version 3.00 for Windows 95 (GraphPad Software,
San Diego/California, USA) or statistical language R
version 1.8.0 (http://www.r-project.org), respectively.
Results
CLINICAL PARAMETERS
The results of the clinical assessment prior to arthro-
scopy are summarized in Table II. Radiographic grading of
OA correlated significantly (P=0.005) with the age of the
patients. There were no significant differences in pain
scores when patients were divided into drug-free subjects
and patients in whom medication was withdrawn prior to
arthroscopy. In 33 of the 41 examined knees (80.5%)
concomitant meniscopathy could be observed during
arthroscopy.
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MARKERS OF INFLAMMATION
Concentrations of PGE2, TxB2 or NO2/3 in synovial fluid
and relative expressions of IL-6, IL-1, COX-2 and iNOS in
synovial membranes are summarized in Table III. TNF
and IL-1 were not detectable in any sample of the synovial
membranes. When patients were divided according to their
age (limit 65 years) into two groups no significant differ-
ences could be observed and only expression of COX-2 in
synovial membrane correlated significantly with the age of
patients (P=0.01). For the various biochemical markers
of inflammation several linear correlations were noted:
between PGE2 and TxB2, iNOS, IL-1, CRP or IL-6 (r=0.60,
P=0.0001; r=−0.53, P=0.04; r=0.69, P=0.005; r=0.39,
P=0.03 or r=0.69, P=0.003, respectively); between TxB2
and IL-6 or IL-1 (r=0.65, P=0.007 or r=0.57, P=0.03,
respectively); between IL-6 and IL-1 (r=0.73, P=0.001) or
CRP (r=0.60, P=0.04).
When concentrating on the most relevant clinical tools
(e.g. K&L grade and WOMAC-index) and endogenous
metabolites of inflammation (e.g. PGE2 and NO2/3 in syn-
ovial fluid) or the corresponding synthesizing enzymes
(COX-2 and iNOS in synovial membranes), respectively,
multiple regression analysis revealed a significant
(P=0.035) linear correlation only between the WOMAC-
index and PGE2 if corrected for age and BMI of the
patients (Pearson’s partial correlation coefficient r=0.36). If
the variables BMI and age were not included into the
multivariate analysis the correlation was of borderline
significance (Pearson’s correlation coefficient r=0.30;
P=0.075).
Table II
Baseline characteristics of the studied patients with OA
age [years] BMI K&L-grade WOMAC-index* WOMAC-pain* VAS-pain* CRP [µg/ml] Histo score
Adult patients 63 33.6 3 35.4 35 40 1.1
(N=25) 48 29.8 3 90.6 70 0 2
54 43.3 2 20.8 30 27 0.7 1
54 27.1 3 62.5 65 12 0.6 1
50 23.5 1 71.9 55 0 2
49 25.2 3 57.3 40 0 0.45 1
62 23.7 2 65.6 70 0 0.9 4
63 30.4 2 51.0 55 0 0.7 3
61 28.7 1 75.0 90 0 0.45 1
62 21.9 1 61.5 60 50 1
45 23.6 3 57.3 65 0 0.45 1
52 30.7 2 81.3 75 10 0.6 1
46 29.3 1 71.9 65 40 0.9
47 23.4 2 62.5 100 0 0.8 3
49 23.8 0 43.8 50 10 0.45 2
52 27.3 2 53.1 45 30 2.2
46 23.2 1 41.7 60 25 0.7 1
63 28.4 1 68.8 45 0 0.45 2
64 28.3 2 68.8 65 15 0.45 3
61 35.6 1 58.3 65 25 0.45 1
51 25.0 1 61.5 75 0 0.45 1
48 30.0 3 40.6 65 0 0.45 0
59 30.0 3 41.7 45 0 0.45 1
59 25.6 3 40.6 60 25 0.45
60 25.9 1 31.3 35 20 0.6 1
Median 54 27.3 2 58.3 60 10 0.53 1.00
Mean 27.9 1.9** 56.6 59.4 13.2 0.67 1.57
SD 4.7 0.9 16.6 16.7 15.6 0.39 0.98
Elderly patients 78 27.7 3 78.1 95 0 2.1 2
(N=16) 78 23.8 3 70.8 60 0 3.4 3
78 23.4 4 43.8 50 32 0.9 2
69 27.6 2 50 65 0 1.1 1
66 35.8 3 32.3 35 0 1.4 1
67 26.0 1 57.3 60 0 2
67 32.2 3 79.2 80 0 0.45 1
66 29.2 3 52.1 40 50 0.45 1
70 23.4 2 32.3 30 25 0.45 2
70 27.2 3 66.7 75 0 0.8 2
68 35.8 3 29.2 40 50 0.45 0
74 27.8 3 43.8 35 0 5.9 5
75 28.2 3 45.8 75 0 0.5 2
66 30.0 3 53.1 45 0 0.45 1
71 24.9 4 67.7 65 45 3
79 19.6 3 71.9 65 0 0.45 1
Median 70 27.6 3 52.6 60 0 0.55 1.00
Mean 27.7 2.9** 54.6 57.2 12.6 0.93 1.68
SD 4.4 0.7 16.4 18.8 20.2 1.05 1.06
*For scoring see Methods (page 2).
**P=0.0023.
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Discussion
In the present cross sectional study we have tested the
hypothesis whether in OA inflammation plays a substantial
role in the development of pain and whether the clinical
state of this disorder is related to biochemical alterations at
the affected site.
Eicosanoids, such as PGE2 or TxB2 are regarded as
markers of (local) inflammatory processes30,31. According
to literature data32 levels of PGE2 in synovial fluid of
patients with OA vary widely (22–2280 pg/ml) which could
be confirmed by our measurements (38–6380 pg/ml) apply-
ing a highly selective GC/MS/MS – assay. There is some
discrepancy to other authors30,33,34 which might be due to
differences in study design, sampling techniques or less
specific analytical methods. Furthermore, low (20–260 pg/
ml) or even undetectable concentrations of TxB2 have been
reported15,31. Similarly in our NSAID-free patients those
levels were in general low (23–943 pg/ml) except for three
patients exhibiting concentrations above this range (7230;
11400 and 15500 pg/ml) which could not be explained by
special clinical, histological or radiological findings.
COX, especially inducible COX-2 represents a key
enzyme for inflammation35. COX-2 has been semiquanti-
fied by immunostaining in synovial blood vessels, lining
cells and sublining layer in different populations including
patients with OA36. In synovial tissue of knees from
patients with OA we found a relative COX-2 expression of
0.35±0.30 (mean±SD).
NO represents another marker of inflammation and
cartilage destruction7,37. In synovial fluid of patients with
OA higher levels of NO compared to normal joints have
been described14,38,39. In general, mean concentrations of
9.1 µM and 4.7 µM have been reported40,41 which are in
good agreement to our data (3.4±2.0 µM). Likewise,
elevated levels of iNOS protein have been found in joints of
patients with OA, even though sometimes iNOS could not
be identified in all assessed samples40,42. In our investiga-
tions we detected iNOS in all assessed synovial mem-
branes. NO production and expression of NOS were
absent in normal cartilage because both depend on stimu-
lation by cytokines8. It has been proposed that inhibition of
NO synthases will decrease the severity of OA7,43. How-
ever, in animal models arthritis can be worsened by NOS-
inhibitors44 questioning the potential of this therapeutic
option.
Proinflammatory cytokines have been measured
primarily in synovial fluid and not in synovial membranes.
As different methods have been used literature data are
quite variable5,45,46. We could not detect TNF and IL-1 in
any synovial membrane sample. Similarly, in synovial fluid
TNF was identified only in 2 of 30 patients with OA30. In
contrast, IL-1 was detectable in 14 from 16 synovial
membranes and IL-6 was present in all samples tested.
According to Smith et al5. IL-1, IL-1 and TNF were
present in synovial membranes and the most marked
changes were seen in late states of OA.
As prevalence and severity of OA is higher in elderly
patients1–3 we divided our patients into two subgroups
(below/above 65 years) and found a trend (P=0.07) for a
higher relative expression of COX-2 in advanced age (see
Table III). Therefore it was not too surprising that between
both variables a significant (P=0.01) linear correlation
existed. Thus, ageing might be a confounding factor when
this parameter is compared in different populations. Like-
wise, a significant (P=0.005) linear correlation between age
and K&L-grade could be observed. As the radiographic
scoring can be used for characterizing a more severe OA
the age-dependent increase of the K&L-grade is in line with
the above epidemiological observations.
Independent of the age of the studied patients we and
others found quite variable concentrations of the assessed
biochemical parameters in the various biological samples.
In addition, when dividing patients according to the median
WOMAC-score of 57 or according to the K&L grade below
and above three into two categories of disease severity no
marked differences in the assessed inflammatory markers
were obvious. Likewise, K&L score did not significantly
correlate with clinical findings in another study47.
In respect to our working hypothesis we could find a
significant (P=0.035) relationship only between the
WOMAC-index and PGE2 if putative confounding factors
such as age and BMI were taken into considerations.
Otherwise no significant linear correlations could be found
between local biomarkers (e.g. PGE2, COX-2, NO2/3,
iNOS) and clinical parameters (e.g. WOMAC-index, K&L-
grade).
In accordance with our findings Nishimura et al.48 did not
observe a significant correlation between concentrations of
IL-1, IL-6 or TNF in synovial fluid and degeneration of
articular cartilage or internal derangements in temporo-
mandibular joints of patients with OA. Furthermore, in other
Table III
Biochemical parameters of studied patients with OA
PGE2 TxB2 NO2/3 iNOS COX-2 IL-1 IL-6
[ng/ml] [ng/ml] [µM] [rel. expr. X/18S]
in synovial fluid in synovial membrane
Age N=37 N=37 N=34 N=16 N=16 N=16 N=17
All patients Median 0.13 0.14 2.69 0.70 0.25 0.39 0.36
Mean 0.46 1.12 3.42 0.79 0.35 0.44 2.41
SD 1.10 3.25 2.00 0.39 0.30 0.53 6.01
Below 65 years Median 0.11 0.17 3.05 0.77 0.18 0.21 0.47
Mean 0.34 1.61 3.63 0.87 0.22* 0.48 0.76
SD 0.54 4.00 1.93 0.30 0.10 0.66 0.75
Above 65 years Median 0.13 0.14 2.37 0.57 0.64 0.40 0.36
Mean 0.70 0.21 3.02 0.64 0.58* 0.38 5.44
SD 1.73 0.23 2.16 0.51 0.39 0.26 9.87
*P=0.07. PGE2=Prostaglandin E2; TxB2=Thromboxan B2; NO2/3=nitric oxide; iNOS=inducible nitric oxide synthase; COX-2=
cyclooxygenase-2; IL-1=interleukin-1; IL-6=interleukin-6; the two age groups were compared by the nonparametric Mann–Whitney-test.
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studies no correlation could be demonstrated between
concentrations of IL-1, IL-6 or TNF in synovial fluid of
temporomandibular joints and age, radiographic findings or
width of mouth opening46,49. Borderie et al.42 could not find
in OA of the knee any correlations between iNOS, IL-1ß,
TNF in synovial fluid and clinical signs. From all this data
one could conclude that apparently no direct relationships
exist between the local levels of the various biochemical
parameters and the severity/ symptoms in OA of the knee
which probably is due to the more local, mainly mechanical
injury with little systemic upset.
It has been postulated that prostaglandins provoke
hyperalgesia by sensitizing pain receptors50–52. Our study
indicates no significant associations between pain, other
clinical or radiographic signs and PGE2 or cytokines. This
would suggest that pain in OA is not provoked primarily by
inflammation but by different mechanisms such as degen-
erative processes, osteophyte growth with stretching of
periosteum, patella cartilage volume, raised introsseous
pressure, microfractures, ligament damage, capsular ten-
sion and meniscal injury53,54. However, based on the cross
sectional character of our study we could not address the
interesting question whether the assessed markers of
inflammation are predictors for the progression of OA. In
addition, due to the restricted sample sizes especially in the
case of the synovial membranes it might be possible that
we have missed some weak associations.
In conclusion, the present study explored in a limited
number of patients with OA different biochemical changes
in joints and their relation to clinical and radiographic signs.
For the first time a large variety of biochemical markers has
been determined concomitantly. From these extensive
assessments it is obvious that in OA of the knee no direct
relationships exist between the local levels of typical
mediators of inflammation and the clinical state of the
disorder. The degenerative condition of this joint disease is
apparently not associated with alterations of the monitored
markers of inflammatory processes. However, it remains to
be proven by a longitudinal study whether inflamma-
tory markers could serve as a predictor of a more rapid
progression of OA.
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